BH.IMMUN&BIO | LYKA LABS | BH.IMMUN&BIO/ LYKA LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.4 | -120.3 | - | View Chart |
P/BV | x | 1.5 | 15.2 | 9.6% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
BH.IMMUN&BIO LYKA LABS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
LYKA LABS Mar-23 |
BH.IMMUN&BIO/ LYKA LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 202 | 25.6% | |
Low | Rs | 21 | 100 | 20.5% | |
Sales per share (Unadj.) | Rs | 10.3 | 30.3 | 34.1% | |
Earnings per share (Unadj.) | Rs | -3.9 | -4.3 | 89.9% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 0.3 | -1,174.3% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 20.4 | 9.1 | 223.9% | |
Shares outstanding (eoy) | m | 43.18 | 30.69 | 140.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 5.0 | 70.3% | |
Avg P/E ratio | x | -9.4 | -35.2 | 26.6% | |
P/CF ratio (eoy) | x | -9.5 | 465.7 | -2.0% | |
Price / Book Value ratio | x | 1.8 | 16.5 | 10.7% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 1,561 | 4,634 | 33.7% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 186 | 81.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 931 | 47.9% | |
Other income | Rs m | 11 | 34 | 31.2% | |
Total revenues | Rs m | 457 | 965 | 47.3% | |
Gross profit | Rs m | -161 | 94 | -170.1% | |
Depreciation | Rs m | 2 | 141 | 1.4% | |
Interest | Rs m | 71 | 119 | 59.5% | |
Profit before tax | Rs m | -223 | -132 | 169.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 0 | 29,626.3% | |
Profit after tax | Rs m | -166 | -132 | 126.5% | |
Gross profit margin | % | -36.0 | 10.1 | -354.9% | |
Effective tax rate | % | 25.3 | 0.1 | 17,804.7% | |
Net profit margin | % | -37.3 | -14.1 | 263.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 442 | 81.0% | |
Current liabilities | Rs m | 940 | 326 | 288.5% | |
Net working cap to sales | % | -130.6 | 12.5 | -1,047.0% | |
Current ratio | x | 0.4 | 1.4 | 28.1% | |
Inventory Days | Days | 85 | 90 | 94.7% | |
Debtors Days | Days | 1,135 | 789 | 143.9% | |
Net fixed assets | Rs m | 1,262 | 1,073 | 117.6% | |
Share capital | Rs m | 432 | 307 | 140.7% | |
"Free" reserves | Rs m | 450 | -27 | -1,676.0% | |
Net worth | Rs m | 882 | 280 | 315.0% | |
Long term debt | Rs m | 0 | 638 | 0.0% | |
Total assets | Rs m | 1,620 | 1,515 | 106.9% | |
Interest coverage | x | -2.2 | -0.1 | 1,965.4% | |
Debt to equity ratio | x | 0 | 2.3 | 0.0% | |
Sales to assets ratio | x | 0.3 | 0.6 | 44.8% | |
Return on assets | % | -5.9 | -0.8 | 698.9% | |
Return on equity | % | -18.9 | -47.0 | 40.2% | |
Return on capital | % | -17.2 | -1.4 | 1,216.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 14.5 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 65 | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 65 | 0 | - | |
Net fx | Rs m | -65 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 90 | 121.7% | |
From Investments | Rs m | 5 | 74 | 6.3% | |
From Financial Activity | Rs m | -147 | -216 | 68.0% | |
Net Cashflow | Rs m | -34 | -53 | 62.9% |
Indian Promoters | % | 59.3 | 54.8 | 108.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 1.0 | - | |
FIIs | % | 0.0 | 0.2 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 45.2 | 90.2% | |
Shareholders | 34,910 | 25,717 | 135.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | LYKA LABS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -1.98% | -0.77% | -0.44% |
1-Month | 6.95% | 16.96% | 2.15% |
1-Year | 21.18% | 17.88% | 49.82% |
3-Year CAGR | -9.18% | 65.97% | 14.21% |
5-Year CAGR | 28.31% | 33.72% | 19.19% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the LYKA LABS share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of LYKA LABS the stake stands at 54.8%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of LYKA LABS.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
LYKA LABS paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of LYKA LABS.
For a sector overview, read our pharmaceuticals sector report.
Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.